386 related articles for article (PubMed ID: 26555316)
1. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.
Bittner T; Zetterberg H; Teunissen CE; Ostlund RE; Militello M; Andreasson U; Hubeek I; Gibson D; Chu DC; Eichenlaub U; Heiss P; Kobold U; Leinenbach A; Madin K; Manuilova E; Rabe C; Blennow K
Alzheimers Dement; 2016 May; 12(5):517-26. PubMed ID: 26555316
[TBL] [Abstract][Full Text] [Related]
2. Elecsys
Lifke V; Kollmorgen G; Manuilova E; Oelschlaegel T; Hillringhaus L; Widmann M; von Arnim CAF; Otto M; Christenson RH; Powers JL; Shaw LM; Hansson O; Doecke JD; Li QX; Teunissen C; Tumani H; Blennow K
Clin Biochem; 2019 Oct; 72():30-38. PubMed ID: 31129184
[TBL] [Abstract][Full Text] [Related]
3. Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.
Shaw LM; Hansson O; Manuilova E; Masters CL; Doecke JD; Li QX; Rutz S; Widmann M; Leinenbach A; Blennow K
Clin Biochem; 2019 Oct; 72():7-14. PubMed ID: 31129181
[TBL] [Abstract][Full Text] [Related]
4. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.
Blennow K; Stomrud E; Zetterberg H; Borlinghaus N; Corradini V; Manuilova E; Müller-Hübner L; Quevenco FC; Rutz S; Hansson O
Clin Chem Lab Med; 2023 Jan; 61(2):234-244. PubMed ID: 36282960
[TBL] [Abstract][Full Text] [Related]
5. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.
Gobom J; Parnetti L; Rosa-Neto P; Vyhnalek M; Gauthier S; Cataldi S; Lerch O; Laczo J; Cechova K; Clarin M; Benet AL; Pascoal TA; Rahmouni N; Vandijck M; Huyck E; Le Bastard N; Stevenson J; Chamoun M; Alcolea D; Lleó A; Andreasson U; Verbeek MM; Bellomo G; Rinaldi R; Ashton NJ; Zetterberg H; Sheardova K; Hort J; Blennow K
Clin Chem Lab Med; 2022 Jan; 60(2):207-219. PubMed ID: 34773730
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J
J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
[TBL] [Abstract][Full Text] [Related]
10. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
[TBL] [Abstract][Full Text] [Related]
11. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
12. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples.
Yamashita K; Watanabe S; Ishiki K; Miura M; Irino Y; Kubo T; Matsui J; Hagino K; Iwanaga S; Yoshida T
Biochem Biophys Res Commun; 2021 Oct; 576():22-26. PubMed ID: 34478915
[TBL] [Abstract][Full Text] [Related]
13. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
14. Multicenter evaluation of analytical characteristics of the Elecsys
Palme S; Christenson RH; Jortani SA; Ostlund RE; Kolm R; Kopal G; Laubender RP
Clin Biochem; 2017 Feb; 50(3):139-144. PubMed ID: 27725167
[TBL] [Abstract][Full Text] [Related]
15. Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
Pannee J; Gobom J; Shaw LM; Korecka M; Chambers EE; Lame M; Jenkins R; Mylott W; Carrillo MC; Zegers I; Zetterberg H; Blennow K; Portelius E
Alzheimers Dement; 2016 Jan; 12(1):55-9. PubMed ID: 26206625
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of a new immunoassay for intact PTH measurement on the Elecsys System 2010 and 1010.
Hermsen D; Franzson L; Hoffmann JP; Isaksson A; Kaufman JM; Leary E; Müller C; Nakatsuka K; Nishizawa Y; Reinauer H; Riesen W; Roth HJ; Steinmüller T; Troch T; Bergmann P
Clin Lab; 2002; 48(3-4):131-41. PubMed ID: 11934215
[TBL] [Abstract][Full Text] [Related]
17. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
[TBL] [Abstract][Full Text] [Related]
18. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
[TBL] [Abstract][Full Text] [Related]
19. Amyloid biomarkers in Alzheimer's disease.
Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
[TBL] [Abstract][Full Text] [Related]
20. Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
Somers C; Goossens J; Engelborghs S; Bjerke M
Biomark Med; 2017 Feb; 11(2):169-178. PubMed ID: 28111962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
